ASH 2018 Conference Coverage

Abstract 1990

Dr Bringhen discusses the ASH 2018 abstract 1990:

1990 – Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies (View Abstract)

Abstract 258

Dr. Takamatsu discusses the ASH 2018 abstract 258:

258 – Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing (View Abstract)

Abstract 1998

Binod Dhakal from the Medical College of Wisconsin discusses ASH 2018 abstract 1998:

1998 – Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM) (View Abstract)

Abstracts 253 and 254

Marc-A. Baertsch from the Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany discusses ASH 2018 abstract 253:

253 – Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse (View Abstract)

254 – Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma (View Abstract)

Abstracts 598, 599 and 1993

Michael Kauffman, MD, PhD,  CEO of Karyopharm Therapeutics Inc. discusses ASH 2018 abstract 589 and 1993:

598 – Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM (View Abstract)

599 – Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd (View Abstract)

1993 – Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma (View Abstract)

Education Conference Coverage ASH 2018 Conference Coverage